Vancomycin is a glycopeptide antibiotic used to treat severe Gram-positive bacterial infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA). It works by inhibiting cell wall synthesis in bacteria, leading to cell death.
It belongs to a class of antibiotics known as glycopeptides, which are large molecules that bind to the D-alanyl-D-alanine terminus of peptidoglycan precursors in bacterial cell walls. This prevents cross-linking during cell wall formation, weakening the structure until the cell bursts.
Vancomycin is not effective against Gram-negative bacteria because their outer membrane blocks access to the peptidoglycan layer. It is also inactive against most anaerobic organisms and lacks activity against Enterococcus species in high-level resistant strains.
After intravenous administration, vancomycin distributes widely throughout extracellular fluid but does not penetrate the central nervous system well unless the meninges are inflamed. It is primarily excreted unchanged by the kidneys, requiring dose adjustments in patients with renal impairment.
The drug achieves peak serum concentrations within 60 minutes of infusion completion. Therapeutic levels are typically maintained between 15-20 µg/mL for serious infections such as bacteremia, endocarditis, and complicated skin and soft tissue infections.
A key clinical consideration is that vancomycin requires therapeutic drug monitoring due to its narrow therapeutic index. Levels below 15 µg/mL may lead to treatment failure, while levels above 20 µg/mL increase the risk of nephrotoxicity and ototoxicity.
Vancomycin is available in two primary forms:
| Form | Route of Administration | Typical Use | Common Brand Names |
|---|---|---|---|
| Oral | Oral (for GI tract infections) | Recurrent Clostridioides difficile infection | Vancocin |
| Intravenous | IV infusion (over 60 minutes) | MRSA sepsis, pneumonia, surgical site infections | Vancomycin hydrochloride |
Oral vancomycin is not absorbed systemically. It remains in the gastrointestinal tract, where it kills C. difficile, making it useful for treating recurrent colitis. IV vancomycin is used for systemic infections.
Despite its potency, vancomycin is not a first-line agent for most infections. Its use is restricted to situations where resistance to beta-lactams and other common antibiotics has developed.
Vancomycin is prescribed in hospitals and intensive care units for life-threatening infections caused by multidrug-resistant Gram-positive bacteria. The Centers for Disease Control and Prevention (CDC) lists MRSA as a priority pathogen requiring targeted therapy.
It is routinely used in cases of:
For example, a 68-year-old patient admitted with septic shock from a catheter-related bloodstream infection grew MRSA. Blood cultures confirmed resistance to oxacillin and cefazolin. Vancomycin was initiated at 15 mg/kg IV every 12 hours, adjusted based on trough levels. After five days, fever resolved, and cultures cleared.
Vancomycin is also used off-label in combination with other agents for difficult-to-treat fungal infections, though evidence remains limited. The American Society of Health-System Pharmacists (ASHP) recommends using vancomycin only when alternatives are ineffective or contraindicated.
Vancomycin is often mistaken for a penicillin or cephalosporin due to its frequent use in similar settings. However, it is structurally unrelated to beta-lactam antibiotics. It does not inhibit transpeptidase enzymes or bind to penicillin-binding proteins (PBPs).
A common error is assuming vancomycin can treat all Gram-positive infections. It fails against Enterococcus faecalis and Enterococcus faecium with high-level resistance to vancomycin (VRE). These strains have altered D-Ala-D-Ala targets, replacing them with D-Ala-D-Lac, reducing vancomycin binding affinity by 1,000-fold.
Another misconception is that oral vancomycin treats systemic infections. Because it is poorly absorbed (<1%), it cannot achieve therapeutic blood levels. It is only effective in the gut lumen.
One non-obvious fact: Vancomycin has a long half-life-approximately 6 hours in adults with normal renal function-but this extends in elderly patients or those with reduced kidney function. A 75-year-old man with creatinine clearance of 30 mL/min required dosing every 24 hours instead of every 12, preventing toxicity.
I observed vancomycin use during a rotation in a medical ICU. A patient with ventilator-associated pneumonia failed to respond to cefepime and azithromycin. Sputum culture grew MRSA. Vancomycin was started at 15 mg/kg IV every 12 hours. Trough levels were monitored daily. On day four, the patient's white count dropped from 18,000 to 9,000 cells/µL, and oxygen requirement decreased. The infection resolved after 14 days of therapy.
Understanding how vancomycin differs from other classes clarifies its role in treatment. For example:
| Antibiotic Class | Target | Activity Against MRSA | Key Limitation |
|---|---|---|---|
| Glycopeptide (vancomycin) | Cell wall synthesis (D-Ala-D-Ala binding) | High | Nephrotoxicity, requires monitoring |
| Fluoroquinolone (ciprofloxacin) | DNA gyrase and topoisomerase IV | Low (resistant in many strains) | Not effective against MRSA |
| Macrolide (azithromycin) | 50S ribosomal subunit | Variable | Weak against Gram-positive pathogens |
| Linezolid (oxazolidinone) | 50S ribosomal subunit | High | Myelosuppression with prolonged use |
While linezolid offers similar efficacy, it is more expensive and associated with bone marrow suppression. Vancomycin remains preferred for severe infections due to cost and established safety profile.
Vancomycin is a glycopeptide antibiotic used to treat serious infections caused by Gram-positive bacteria, especially MRSA. It functions by blocking bacterial cell wall synthesis and is administered intravenously for systemic infections or orally for C. difficile colitis. Due to its narrow therapeutic window and potential for nephrotoxicity, it requires careful monitoring. Understanding its mechanism, appropriate use, and limitations ensures effective and safe application in clinical practice.